Diisopropylethylamine → (9R,11S, 14S)-14-tert-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-13-oxo-8-oxa-12,15-diazatetracyclo[20.3.1.12,6.19,12]octacosa-1(26),2(28),3,5,22,24-hexaene-11-carboxamide

HRID 1879262ノート

反応式

HRID 1879262 の反応式
[Cl-].[CH:2]1([S:5]([NH:8][C:9]([C@@:11]2([NH3+:16])[CH2:13][C@H:12]2[CH:14]=[CH2:15])=[O:10])(=[O:7])=[O:6])[CH2:4][CH2:3]1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[C:41]([C@@H:45]1[NH:69][CH2:68][CH2:67][CH2:66][CH2:65][CH2:64][CH2:63][C:62]2[CH:70]=[C:58]([CH:59]=[CH:60][CH:61]=2)[C:57]2=[CH:71][C:53](=[CH:54][CH:55]=[CH:56]2)[CH2:52][O:51][C@H:50]2[CH2:72][N:47]([C@H:48]([C:73](O)=[O:74])[CH2:49]2)[C:46]1=[O:76])([CH3:44])([CH3:43])[CH3:42].CCN(C(C)C)C(C)C>CN(C=O)C>[C:41]([C@@H:45]1[NH:69][CH2:68][CH2:67][CH2:66][CH2:65][CH2:64][CH2:63][C:62]2[CH:70]=[C:58]([CH:59]=[CH:60][CH:61]=2)[C:57]2=[CH:71][C:53](=[CH:54][CH:55]=[CH:56]2)[CH2:52][O:51][C@H:50]2[CH2:72][N:47]([C@H:48]([C:73]([NH:16][C@:11]3([C:9]([NH:8][S:5]([CH:2]4[CH2:4][CH2:3]4)(=[O:7])=[O:6])=[O:10])[CH2:13][C@H:12]3[CH:14]=[CH2:15])=[O:74])[CH2:49]2)[C:46]1=[O:76])([CH3:44])([CH3:42])[CH3:43]

参加物

6

反応物 4

HCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 58005162(9R,11S,14S)-14-tert-butyl-13-oxo-8-oxa-12,15-diazatetracyclo[20.3.1.12,6.1 9,12]octacosa-1(26),2(28),3,5,22,24-hexaene-11-carboxylic acidHCID 86637110[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]azanium chloride

生成物 1

HCID 86637109(9R,11S, 14S)-14-tert-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-13-oxo-8-oxa-12,15-diazatetracyclo[20.3.1.12,6.19,12]octacosa-1(26),2(28),3,5,22,24-hexaene-11-carboxamide

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

(1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropanaminium chloride 48 (prepared as described in WO 03/099274) (1.2 eq.) and HATU (1.2 eq.) were added to a 0.1M solution of (9R,11S,14S)-14-tert-butyl-13-oxo-8-oxa-12,15-diazatetracyclo[20.3.1.12,6.19,12]octacosa-1(26),2(28),3,5,22,24-hexaene-11-carboxylic acid 105 in DMF containing DIPEA (4.0 eq.). The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated to dryness, dissolved in DMSO and purified by RP-HPLC (stationary phase: column WATERS XTERRA C18, 5 μm, 19×150. Mobile phase: MeCN/H2O buffered with 0.1% TFA from 30% to 90% of MeCN in 14 minutes, run time 18 minutes). Fractions containing the pure compound were combined and freeze dried to afford compound 142 (TFA salt) as an off white solid (30% over 4 steps). 1H NMR (400 MHz, DMSO-d6, 300 K) δ 10.65 (s, 1H), 8.89 (s, 1H), 8.65-8.49 (bs, 1H), 8.25-8.11 (bs, 1H), 7.62-7.56 (m, 2H), 7.51-7.38 (m, 4H), 7.31 (d, J 7.3, 1H), 7.24 (d, J 7.3, 1H), 5.69-5.53 (m, 1H), 5.24 (d, J 17.2, 1H), 5.14 (d, J 11.9, 1H), 4.71 (d, J 12.4, 1H), 4.61 (d, J 12.4, 1H), 4.31 (bt, 1H), 4.37 (bs, 1H), 4.16 (d, J 8.8, 1H), 4.04 (d, J 11.9, 1H), 3.79 (dd, J 11.5, 3.9, 1H), 3.00-2.91 (m, 1H), 2.91-2.81 (m, 1H), 2.80-2.68 (m, 2H), 2.22 (q, J 17.5, 8.8, 1H), 2.02-1.91 (m, 1H), 1.83-1.69 (m, 2H), 1.68-1.56 (m, 2H), 1.41-1.24 (m, 5H), 1.22-1.02 (m, 13H), 0.91 (t, J 7.3, 4H). MS (ES+) m/z 705 (M+H)+.

後処理

  1. concentrationThe reaction mixture was concentrated to dryness
  2. dissolutiondissolved in DMSO
  3. custompurified by RP-HPLC (stationary phase: column WATERS XTERRA C18, 5 μm, 19×150. Mobile phase: MeCN/H2O buffered with 0.1% TFA from 30% to 90% of MeCN in 14 minutes, run time 18 minutes)
  4. additionFractions containing the pure compound
  5. customfreeze dried

出典と根拠

ORDレコード
ord-95a3615cfb4644f59f0b6b3def1b9c2f
出典データセット
uspto-grants-2012_11
特許番号
US08314062B2

反応ノート

読み込み中…